Ann: Investor Presentation by Cogstate Executives, page-2

By hosting this event it might be a sign that they are seeing a return to positive momentum in the clinical trials business. It would be strange to highlight this to area to the market and then turn around a few weeks later and say "jam tomorrow".

Supportive of this fact, the only other serious player in the CNS Cognition space reported a few days ago and said after a quiet 9 to 12 months the conversion from their backed up pipeline is starting to normalize. They said biotech remains a weak sport but the far more important, global pharma clients are starting to pull triggers again. Also that the number of early stage conversations and sales leads has increased significantly in the last few months. Given they fish in the same ponds but are rarely in direct competition, one might assume the same applies to Cogsate as well !